On August 1, 2024, Cari Gallman, EVP of Corporate Affairs at Bristol-Myers Squibb (BMY), engaged in a transaction involving the company's common stock. Gallman executed a sale of 384 shares at a price of $48.17 per share, resulting in a total transaction value of $18,497.28. This sale was part of a transaction coded 'F', typically indicating a payment of exercise price or tax liability by delivering or withholding securities. Additionally, Gallman acquired 1,061 shares through an exercise or conversion of derivative security, coded 'M', at no cost. Following these transactions, Gallman's direct holdings in Bristol-Myers Squibb common stock amounted to 2,109 shares.

On August 1, 2024, Cari Gallman, EVP of Corporate Affairs at Bristol-Myers Squibb (BMY), engaged in a transaction involving the company's common stock. Gallman executed a sale of 384 shares at a price of $48.17 per share, resulting in a total transaction value of $18,497.28. This sale was part of a transaction coded 'F', typically indicating a payment of exercise price or tax liability by delivering or withholding securities. Additionally, Gallman acquired 1,061 shares through an exercise or conversion of derivative security, coded 'M', at no cost. Following these transactions, Gallman's direct holdings in Bristol-Myers Squibb common stock amounted to 2,109 shares.